RxDoctor Payments Data

Janpreet Mokha, MD

Critical Care Medicine · Middletown, NYNPI 1548649023

Payments from drug & device makers

$1,631in general payments, 2019–2025

Across 70 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$519
  • Sanofi$425
  • AstraZeneca$248
  • Sanofi-aventis U.S. LLC$178
  • Verona Pharma, Inc.$80
  • Mylan Specialty L.p.$63
  • plus $118 from 5 others

What the payments were for

  • Food & beverage$1,45389%
  • Education$17811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,631 in reported general payments places this provider in the 80th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York

Medicare billing

Part B allowed, 2024
$176,236
Medicare patients
433
Services billed
1,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$37,240
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$14,201
Incruse ElliptaUmeclidinium Bromide30$10,658
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,608
SymbicortBudesonide/Formoterol Fumarate21$6,057
BreynaBudesonide/Formoterol Fumarate18$4,269
Albuterol Sulfate HfaAlbuterol Sulfate78$2,750
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$1,977
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$1,405
Fluticasone Propionate15$174
Montelukast Sodium14$105
Prednisone21$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$15$62,099117 claims
AstraZenecaBreztri Aerosphere, Symbicort$248$14,66535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 442 critical care medicine providers in New York.

Other critical care medicine in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →